Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | NAAA | Q02083 | 5/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18352484 | 0.94 | LMNA (0.41) | LMNANAAAHRH4HRH3MGLL | |
| SCHEMBL18355335 | 0.92 | HRH4 (0.40) | NAAAHRH4HRH3EPHX1EPHX2 | |
| SCHEMBL18355231 | 0.91 | LMNA (0.40) | LMNANAAAHRH4HRH3HCAR2 | |
| SCHEMBL18355110 | 0.87 | CTSK (0.36) | LMNANAAAHRH4HRH3HCAR2 | |
| SCHEMBL18352604 | 0.86 | HRH4 (0.43) | LMNANAAAHRH4HRH3EPHX1 | |
| SCHEMBL18355138 | 0.83 | TSHR (0.40) | LMNAHRH4HRH3 | |
| SCHEMBL18354874 | 0.82 | EPHX1 (0.53) | NAAAKEAP1NFE2L2HCAR2EPHX1 | |
| SCHEMBL18364176 | 0.81 | EPHX1 (0.44) | EPHX1EPHX2 | |
| SCHEMBL18355260 | 0.81 | EPHX1 (0.41) | NAAAKEAP1NFE2L2HCAR2EPHX1 | |
| SCHEMBL18354886 | 0.80 | HRH4 (0.38) | NAAAHRH4HRH3HCAR2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170001953-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-01-05 | — | — | US | disclosed |
| US-20170001953-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001953-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, FPGS, APC | LMNA 4358/4885NAAA 2343/4885HRH4 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.